Abstract
The Fontan operation accomplishes complete separation of systemic venous blood from pulmonary venous circulation in patients with single ventricle anatomy. Operative survival since the first description of the Fontan operation is excellent in the current era through modifications in surgical techniques, identification of patient-specific risk factors, and advances in postoperative care. Improved early outcomes have also resulted in a decline in late mortality for patients who have undergone staged palliation with the Fontan operation. As the number of late survivors from the Fontan operation increases, caregivers will be evermore faced with the challenge of recognizing and managing the patient with failing Fontan physiology. Even after excellent early results, patients with single ventricle lesions remain at risk of progressive ventricular dysfunction, dysrhythmias, progressive hypoxemia, elevated pulmonary vascular resistance, and protein-losing enteropathy, which can result in morbidities including but not limited to, myocardial failure, thromboembolism, and stroke. Consequently, continued long-term survival of patients who undergo the Fontan operation is dependent upon preservation of single ventricle function, avoidance of late complications, and, in the patient with a failing Fontan, recognition and treatment of the underlying pathophysiologic process that has resulted in Fontan failure.
References
Bendayan I, Casaldaliga J, Castello F, et al. (2000) Heparin therapy and reversal of protein-losing enteropathy in a case with congenital heart disease. Pediatr Cardiol 21:267–268
Border WL, Syed AU, Michelfelder EC, et al. (2003) Impaired systemic ventricular relaxation affects postoperative short-term outcome in Fontan patients. J Thorac Cardiovasc Surg 126:1760–1764
Bruns LA, Chrisant MK, Lamour JM, et al. (2001) Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138:505–511
Burkhart HM, Dearani JA, Mair DD, et al. (2003) The modified Fontan procedure: early and late results in 132 adults. J Thorac Cardiovasc Surg 125:1252–1259
Cesario D, Clark J, Maisel A (1998) Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 135:121–129
Chakrabarti S, Keeton BR, Salmon AP, et al. (2003) Acquired combined immunodeficiency associated with protein losing enteropathy complicating Fontan operation. Heart 89:1130–1131
Cheung YF, Penny DJ, Redington AN (2000) Serial assessment of left ventricular diastolic function after Fontan procedure. Heart 83:420–424
Donnelly JP, Rosenthal A, Castle VP, et al. (1997) Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 130:474–478
Driscoll DJ, Offord KP, Feldt RH, et al. (1992) Five- to fifteen-year follow-up after Fontan operations. Circulation 85:469–496
Feldt RH, Driscoll DJ, Offord KP, et al. (1996) Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 112:672–680
Fonarow G (2003) B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure. Heart Failure Rev 8:321–325
Gentles TL, Gauvreau K, Mayer JE, et al. (1997) Functional outcome after the Fontan operation: factors influencing late morbidity. J Thorac Cardiovasc Surg 114:392–403
Gewillig M (1994) The Fontan circulation: late functional results. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 6:56–63
Hennein HA (2002) The Fontan operation for hypoplastic left heart syndrome. In: Hennein HA, Bove EL (eds) Hypoplastic Left Heart Syndrome 2002. Futura, New York, pp 155–178
Heragu N, Mahony L (1999) Is captopril useful in decreasing pleural drainage in children after modified Fontan operation. Am J Cardiol 84:1109–1112
Hjortdal VE, Stenberg EV, Ravn HB, et al. (2000) Neurohumoral activation late after cavopulmonary connection. Heart 83:439–443
Hoffman TM, Wernovsky G, Atz AM, et al. (2003) Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 107:996–1002
Jacobs ML, Rychik J, Byrum CJ, et al. (1996) Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration. Ann Thorac Surg 61:206–208
Khambadkone S, Li J, de Leval MR, et al. (2003) Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 107:3204–3208
Kim S, In-Seung P, Song J, et al. (2004) Reversal of protein-losing enteropathy with calcium replacement in a patient after Fontan operation. Ann Thorac Surg 77:1456–1457
Knott-Craig CJ, Danielson GK, Schaff HV, et al. (1995) The modified Fontan operation: an analysis of risk factors for early postoperative death or takedown in 702 consecutive patients from one institution. J Thorac Cardiovasc Surg 109:1237–1243
Kukin ML (2002) β-Blockers in chronic heart failure: considerations for selecting an agent. Mayo Clinic Proc 77:1199–1206
Lenz D, Hambsch J, Schneider P, et al. (2003) Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection? Crit Care 7:185–190
Levy M, Danel C, Laval A, et al. (2003) Nitric oxide synthase expression by pulmonary arteries: a predictive marker of Fontan procedure outcome? J Thorac Cardiovasc Surg 125:1083–1090
Lopez-Candales A, Vora T, Gibbons W, et al. (2002) Symptomatic improvement in patients treated with intermittent infusion of inotropes: a double-blind placebo controlled pilot study. J Med 33:129–146
Mahle WT, Coon PD, Wernovsky G, et al. (2001) Quantitative echocardiographic assessment of the performance of the functionally single right ventricle after the Fontan operation. Cardiol Young 11:399–406
Mainwaring RD, Lamberti JJ, Carter TL, et al. (1995) Renin, angiotensin II, and the development of effusions following bidirectional Glenn and Fontan procedures. J Card Surg 10:111–118
Mair DD, Hagler DJ, Puga FJ, et al. (1992) Fontan operation in 176 patients with tricuspid atresia. Results and a proposed new index for patient selection. Circulation 82(Suppl IV):IV-164–IV-169
Mair DD, Puga FJ, Danielson GK (2001) The Fontan procedure for tricuspid atresia: early and late results of a 25-year experience with 216 patients. J Am Coll Cardiol 37:933–939
Marino BS (2002) Outcomes after the Fontan procedure. Curr Opin Pediatr 14:620–626
Marshall J, Berkenbosch JW, Russo P (2004) Preliminary experience with nesiritide in the pediatric population. J Intens Care Med 19:164–170
Merten L, Hagler DJ, Sauer U, et al. (1998) Protein losing enteropathy after the Fontan operation: an international multicenter study. J Thorac Cardiovasc Surg 115:1063–1073
Murch SH, Winyard PJD, Koletzko S, et al. (1996) Congenital enterocyte heparan sulfate deficiency with massive albumin loss, secretory diarrhea, and malnutrition. Lancet 347:1299–1301
Ohuchi H, Hasegawa S, Yasuda K, et al. (2001) Severely impaired cardiac autonomic nervous activity after the Fontan operation. Circulation 104:1513–1518
Pfeffer MA, Braunwald E, Moye LA, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 327:669–667
Powell AJ, Gauvreau K, Jenkins KJ, et al. (2001) Perioperative risk factors for development of protein-losing enteropathy following a Fontan procedure. Am J Cardiol 88:1206–1209
Ringel RE, Peddy SB (2003) Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol 91:1031–1032
Rothman A, Mayer JE, Freed MD (1987) Treatment of chronic pleural effusions after the Fontan procedure with prednisone. Am J Cardiol 60:408–409
Rychik J, Spray TL (2002) Strategies to treat protein-losing enteropathy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 5:3–11
Sensaki H, Masutani S, Kobayashi J, et al. (2002) Ventricular afterload and ventricular work in Fontan circulation: comparison with normal two-ventricle circulation and single-ventricle circulation with Blalock–Taussig shunts. Circulation 105:2885–2892
Silverman A, Roy CC (1983) Protein-losing enteropathy. In: Silverman A, Roy CC, (eds) Pediatric Clinical Gastroenterology, 3rd edn. Mosby, St. Louis, pp 304–323
Sorenson GK, Ramamoorthy C, Lynn AM, et al. (1996) Hemodynamic effects of amrinone in children after Fontan surgery. Anesth Analg 82:241–246
Stewart JM, Gewitz MH, Clark BJ, et al. (1991) The role of vasopressin and atrial natriuretic factor in postoperative fluid retention after the Fontan procedure. J Thorac Cardiovasc Surg 102:821–829
Stier CT Jr, Koenig S, Lee DY, et al. (2003) Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (inspra). Heart Dis 5:102–118
Therrien J, Webb GD, Gatzoulis MA (1999) Reversal of protein losing enteropathy with prednisone in adults with modified Fontan operations: long term palliation or bridge to cardiac transplantation? Heart 82:241–243
Zellers TM, Brown K (1996) Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol 17:115–117
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghanayem, N.S., Berger, S. & Tweddell, J.S. Medical Management of the Failing Fontan. Pediatr Cardiol 28, 465–471 (2007). https://doi.org/10.1007/s00246-007-9007-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-007-9007-0